Obsessive-compulsive disorder (OCD) and related disorders comprise a heterogeneous group of neuropsychiatric conditions characterized by intrusive thoughts and repetitive behaviors. While traditionally conceptualized as disorders of compulsivity, emerging evidence supports a dimensional model in which impulsivity represents a critical and interacting construct that influences clinical presentation, comorbidity patterns, and treatment response. This interaction is increasingly understood through dysfunction within cortico-striato-thalamo-cortical circuitry and associated large-scale brain networks that regulate reward processing, habit formation, and executive control. Comorbidity with impulsivity-related conditions, including attention-deficit/hyperactivity disorder (ADHD), body dysmorphic disorder, autism spectrum disorder, and addictive behaviors, introduces additional complexity and may significantly interfere with engagement in standard treatments such as ERP. Recent advances in neuroimaging and neurocognitive research have identified impairments in frontoparietal control networks and hub regions involved in cognitive flexibility and inhibitory control, providing a mechanistic framework for the coexistence of impulsive and compulsive features. Pharmacological management further reflects this complexity. While selective serotonin reuptake inhibitors remain first-line treatments for compulsivity, patients with prominent impulsivity or comorbid ADHD often demonstrate an incomplete response. Emerging evidence suggests that targeted pharmacologic strategies, including stimulant and nonstimulant agents, may enhance top-down cognitive control and improve engagement with behavioral therapies when applied judiciously. This narrative review synthesizes current neurobiological, clinical, and pharmacological evidence to examine the multidimensional relationship between impulsivity and compulsivity across OCD spectrum disorders. It proposes a sequential treatment framework in which stabilization of impulsivity and disruptive comorbidities precedes intensive OCD-focused intervention. Integrating dimensional psychiatry with neurobiological insights may improve treatment planning, enhance therapeutic engagement, and optimize outcomes in complex OCD presentations.
Bohall et al. (Fri,) studied this question.